جست‌وجوی استاد و پژوهشگر

Matthias Mannمشاهده پروفایل

استاد

• Mass Spectrometry
• Proteomics
• Systems Biology
• +۶ مورد دیگر

Professor Matthias Mann is a world-leading scientist serving as Director of the Proteomics and Signal Transduction department at the Max Planck Institute of Biochemistry in Martinsried, Germany, and Director of the Proteomics department at the Novo Nordisk Foundation Center for Protein Research, Faculty of Health Sciences, University of Copenhagen, Denmark. With an h-index exceeding 277 and over 350,000 citations, he is recognized as the highest cited German researcher and one of the most influential scientists globally in proteomics. His educational background includes: Ph.D. in Chemical Engineering from Yale University (1988) Master's Degree in Physics from Georg August University Göttingen (1984) Bachelor's of Arts in Mathematics from Georg August University Göttingen (1982) Professor Mann's research focuses on advancing mass spectrometry-based proteomics to understand biological systems at the protein level. His work spans technological developments in mass spectrometry, bioinformatics and computational analysis, signal transduction and posttranslational modifications, and clinical proteomics applications for disease diagnosis and treatment. The Mann lab has pioneered groundbreaking methods like SILAC for quantitative proteomics and MaxQuant for proteome data analysis. Their vision is to translate proteomics knowledge into clinical practice for predictive, diagnostic, and preventive medicine, with recent work focusing on AI-guided platforms for analyzing proteomes from minimal tissue samples. Analysis of Professor Mann's recent publications reveals a strong trend toward clinical applications of proteomics, particularly in cancer research, metabolic diseases, and neurodegenerative disorders. His work increasingly integrates spatial proteomics, single-cell resolution techniques, and artificial intelligence approaches to uncover disease mechanisms and identify potential biomarkers, with a clear shift from basic technology development toward direct clinical applications and personalized medicine. Professor Mann has received numerous prestigious awards throughout his career: 2025: Elected member of the American National Academy of Sciences 2024: Dr. H.P. Heineken Award for Biochemistry and Biophysics 2023: Otto Warburg Medal 2019: Nominated member of the Bavarian Academy of Sciences 2013: Elected member of Leopoldina German National Academy of Sciences 2012: Körber European Science Award, Louis-Jeantet Foundation Prize for Medicine, Ernst Schering Prize, and Leibniz Prize Professor Mann leads a highly collaborative research team involved in multiple international networks including the Bill & Melinda Gates Foundation, Michael J. Fox Foundation for Parkinson's Research, CLINSPECT-M, and Munich Heart Alliance. His lab has mentored numerous successful researchers, with several former postdocs receiving prestigious ERC Starting Grants. The Mann group has developed innovative clinical proteomics pipelines for analyzing archived tissue specimens and body fluids, aiming to identify protein markers for early detection of diseases such as diabetes and cancer. The Mann lab operates across two major research centers with state-of-the-art mass spectrometry facilities. Their Clinical Knowledge Graph platform integrates multi-omics data with extensive metadata, creating an ecosystem for machine learning applications in proteomics. Current research focuses on developing highly sensitive methods that can profile thousands of proteins from minimal cell samples, enabling the identification of critical disease-related proteins and supporting the development of individualized therapies.

Waldemar Kolanusمشاهده پروفایل

استاد

• Molecular Immunology
• Cell Signaling
• Signal Transduction Pathways
• +۴ مورد دیگر

Prof. Waldemar Kolanus leads the Molecular Immunology and Cell Biology department at the University of Bonn's Life & Medical Sciences Institute (LIMES) . His research bridges immunoregulation , stem cell dynamics , and metabolic stress responses in immune cells. Unit 2 member at LIMES Principal investigator in SFB 704 and ImmunoSensation Cluster Leads a multidisciplinary lab with postdocs, PhD students, and technical staff His work focuses on intracellular signaling pathways connecting immune activation to tissue homeostasis, particularly through: Cytohesin proteins in integrin-mediated adhesion and migration TRIM71 in stem cell regulation and congenital hydrocephalus High-salt environments affecting macrophage function Publication trends show expertise in immune cell migration , genetic models , and chemical inhibition , with frequent use of mice and zebrafish for in vivo studies. Key articles explore: TRIM71's dual role in auditory development and germ cell maintenance Cytohesin family's Golgi regulation and insulin signaling Ruxolitinib's off-target migration inhibition of dendritic cells Contact details: Address: LIMES Institute, Carl-Troll-Straße 31, Bonn Email: kolanus.sekretariat@uni-bonn.de Phone: +49 228 73-62788

• Stem Cell Biology
• Genetic Engineering
• Epigenetics
• +۵ مورد دیگر

Konstantinos Anastassiadis is a Professor at the Center for Molecular and Cellular Bioengineering (CMCB) of Dresden University of Technology , leading the Stem Cell Engineering group at the Biotechnology Center (BIOTEC) . His research focuses on unraveling molecular pathways regulating stem cell self-renewal and lineage commitment, with a strong emphasis on genetic engineering tool development and epigenetic mechanisms during cellular reprogramming. The lab utilizes mouse and human embryonic stem cells, neural stem cells, mesenchymal stromal cells, and induced pluripotent stem cells (iPSCs) in their investigations. Core Research Areas: Molecular regulation of stem cell fate Epigenetic mechanisms (e.g., UTX/UTY histone demethylases) Genetic engineering tool development (Flp, Dre, Vika recombinases, CRISPR protocols) Conditional immortalization systems for rare cell expansion Publications highlight his contributions to understanding: Role of histone methyltransferases (MLL1, MLL2, Setd1b) in hematopoiesis and cancer Epigenetic regulation during mouse development and spermatogenesis Genetic tools for protein tagging, transposon-mediated BAC transgenesis Interactions between stem cells and niche microenvironments Transcriptional and mechanical markers during reprogramming Collaborations span immunology , developmental biology , and bioinformatics . The lab actively participates in teaching activities at CMCB and maintains a focus on translational applications of stem cell research.

Kathrin Schumannمشاهده پروفایل

استادیار

• CRISPR-based Gene Editing
• Immune Cell Engineering
• Cell Therapy Development
• +۳ مورد دیگر

Prof. Dr. Kathrin Schumann is an Assistant Professor at the Technical University of Munich (TUM), leading the 'Engineering Immune Cells for Therapy' group within the TUM School of Medicine and Health. Her research focuses on CRISPR-based engineering of human immune cells to develop novel therapies for autoimmune and tumor diseases. She holds a doctorate from the Max Planck Institute of Biochemistry and has conducted postdoctoral research at the University of California, San Francisco, under Professors Alex Marson and Jeffrey Bluestone. Dr. Schumann’s academic career includes a Presidential Postdoc Fellowship at Novartis (Basel) and a tenure-track appointment at TUM since 2018. Her work emphasizes genomic editing of T cells to study gene function and improve cell therapy safety. Key research themes include CRISPR-mediated gene silencing, T cell receptor engineering, and HIV-host interaction studies. Education: Bachelor/Master in Biochemistry, University of Tübingen PhD, Max Planck Institute of Biochemistry (Martinsried) Postdoc, University of California, San Francisco (UCSF) Her research has yielded breakthroughs in CRISPR applications for T cell therapy, including PD-1 disruption to enhance anti-tumor efficacy and targeted editing of T cell receptors. Awards include a DFG research grant (2016). Notable achievements include the development of CRISPR ribonucleoprotein platforms for primary T cells and insights into metabolic checkpoints in T cell exhaustion. Her lab collaborates globally to translate CRISPR-based discoveries into clinical therapies.

Andrew Bassettمشاهده پروفایل

پژوهشگر

• Genome Engineering
• Neurodegenerative Diseases
• Stem Cell Research
• +۵ مورد دیگر

Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.

• Neuro-oncology
• Neuropathology
• Glioblastoma
• +۳ مورد دیگر

Professor Patrick Harter is a faculty member at the Institute of Neuropathology, Ludwig Maximilian University of Munich (LMU), where he leads research in neuro-oncology and molecular diagnostics of CNS tumors. His work focuses on glioblastoma, meningioma, and brain metastasis, with emphasis on epigenetic mechanisms like DNA methylation and metabolic adaptations in the tumor microenvironment. Research interests span: Molecular classification of brain tumors using DNA methylation profiling Therapeutic targeting of BRAF/MEK and PI3K/Akt/mTOR pathways Role of hypoxia and metabolic plasticity in treatment resistance Liquid biopsy development for non-invasive tumor monitoring His recent publications demonstrate a strong trend toward integrating epigenetic, metabolic, and immunotherapeutic approaches. Articles frequently explore: Novel biomarkers for tumor grading and prognosis Mechanisms of therapy resistance in gliomas Impact of tumor microenvironment on metastasis

G. Petur Nielsenمشاهده پروفایل

استاد

• Bone and Soft Tissue Pathology
• Molecular Genetics of Bone Tumors
• Chordoma Research
• +۵ مورد دیگر

G. Petur Nielsen, MD is a Professor of Pathology at Harvard Medical School and serves as Subspecialty Head, Bone and Soft Tissue Pathology at Massachusetts General Hospital . With a clinical focus on bone and soft tissue tumors, his expertise spans diagnostic pathology, molecular genetics of neoplasms, and ancillary testing applications. Research interests center on Pathology and biology of bone/soft tissue tumors Molecular genetics of bone and soft tissue neoplasms Chordoma and sarcoma research Epithelioid vascular tumor differentiation Mesenchymal tumors of the female genital tract His work includes landmark studies on tumor misdiagnosis rates, immunohistochemical profiling, and genomic analysis of chordomas. Scientific contributions appear in leading journals like Nature and American Journal of Surgical Pathology , with major emphasis on Molecular tumor classification Mutational signature analysis Translational oncology Diagnostic accuracy improvement Genomic instability mechanisms

Thomas Spallekمشاهده پروفایل

پژوهشگر

• Plant Biology
• Parasitic Plant Genetics
• Plant-Microbe Interactions
• +۴ مورد دیگر

Dr. Thomas Spallek is a Junior Group Leader leading the Plant Biotic Interactions Group at Georg-August University Göttingen, Germany. His research focuses on functional genetics of parasitic plants, interspecific signaling, and haustoria formation mechanisms. Previously, he held roles as Project Leader (2019–2022) and Postdoc (2018–2019) at the University of Hohenheim, with postdoctoral experience at RIKEN (Japan) and The Sainsbury Laboratory (UK). Education: PhD in Plant Biology (Max Planck Institute, Cologne, 2011), Diploma in Biology (University of Konstanz, 2008). Research Interests: Parasitic plant genetics and host interactions Cytokinin signaling in plant-pathogen relationships Cellular and molecular mechanisms of haustorium development Publications span plant-parasite signaling, hormonal regulation, and genomic studies of parasitic weeds. Notable collaborations include work on Striga asiatica genome analysis and cytokinin-driven virulence factors. He is affiliated with the International Research Training Group 2172 - PRoTECT and coordinates the Plant Biotic Interactions research group. His work integrates molecular genetics, bioimaging, and computational tools to dissect plant defense and parasitic strategies.

Mathias Munschauerمشاهده پروفایل

پژوهشگر

• Molecular Virology
• RNA Biology
• Host-Pathogen Interactions
• +۷ مورد دیگر

Mathias Munschauer leads the Department of Molecular Virology at Heidelberg University's Faculty of Medicine, within the Center for Infectious Diseases. His research group focuses on unraveling RNA regulatory mechanisms that govern viral infection outcomes, with emphasis on HCV, HBV, and Dengue virus. His research interests lie at the intersection of RNA biology and virology, particularly in understanding how viral RNA molecules interact with host cell components. The lab employs cutting-edge methodologies including RAP-MS and SHIFTR for RNA interactomics, integrated with functional genomics, single-cell transcriptomics, and AI-driven analysis of high-dimensional data. This systems-level approach enables the identification of host factors and regulatory pathways critical for viral replication and immune evasion. The recent publications highlight a strong trend toward spatially and temporally resolved analysis of RNA-protein interactions across diverse RNA viruses. There is a consistent focus on developing and applying innovative technologies to map host-virus interfaces, with applications in identifying antiviral targets and understanding infection mechanisms. The work spans molecular, cellular, and systems biology, with increasing integration of computational and machine learning approaches. Systems virology RNA-protein interactomics Host-pathogen interactions CRISPR screening Single-cell analysis Antiviral strategies Dr. Munschauer mentors a research team and contributes to the doctoral program in Infectious Diseases. His lab develops and shares novel reagents and methods, fostering collaborative science. While specific grants are not listed, the technological sophistication suggests substantial funding support. The lab operates within a vibrant research environment alongside other virology groups such as AG Bartenschlager and AG Ruggieri. The Munschauer Lab is part of a larger virology and infectious disease research ecosystem at Heidelberg University, collaborating across disciplines to advance understanding of viral pathogenesis. The team actively develops and applies innovative tools for RNA-centric discovery, positioning the group at the forefront of molecular virology.

Simone Spulerمشاهده پروفایل

استاد

• Muscle Stem Cell Biology
• CRISPR/Cas9 and Base Editing
• Muscular Dystrophies
• +۳ مورد دیگر

Prof. Dr. Simone Spuler is a leading researcher in muscle stem cell biology and gene therapy at the Experimental and Clinical Research Center (ECRC) in Berlin, jointly affiliated with Charité - Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine. She serves as Director of the University Outpatient Clinic for Muscle Diseases, focusing on translational approaches for genetic and age-related muscle disorders. Develops CRISPR/Cas9 and base editing therapies for muscular dystrophies (LGMD2A, Dysferlinopathy) Translates stem cell research into clinical trials like MuST and BASKet Validates GMP-compliant manufacturing of primary human satellite cells (PHSats) for ATMP applications Her research interests center on muscle stem cell heterogeneity, regenerative medicine, and epigenetic mechanisms in critical illness myopathy. Recent work explores: CRISPR editing of patient-derived stem cells Humanized mouse models for dystrophy validation Epigenetic reprogramming in ICU-acquired weakness Decellularization protocols for diaphragm repair She leads a multidisciplinary team working on: Genome editing of CAPN3, LMNA, and Dysferlin mutations Stem cell expansion using bacterial nanocellulose Development of regenerative therapies for urinary incontinence Scientific awards include: Science4Life Venture Cup 2019 (Pharma Category) NLSInvest Award 2022 Einstein Visiting Fellowship (2019-2022) Her clinical and entrepreneurial efforts involve founding the startup MyoPax , which develops stem cell therapies for incurable muscle diseases, supported by grants from the German Federal Ministry of Education and Research (BMBF) and Else Kröner-Fresenius Foundation (EKFS). The MuST clinical trial for epispadias patients is funded with €4.3M. Her team collaborates with patient organizations like Coalition to Cure Calpain 3 and Deutsche Gesellschaft für Muskelkranke .

Jörn Walterمشاهده پروفایل

استاد

• Epigenetics
• Genetics
• Epigenomics
• +۵ مورد دیگر

Prof. Dr. Jörn Walter serves as a Senior Professor for Genetics and Epigenetics at Saarland University's Faculty of Natural Sciences and Technology. His laboratory investigates epigenetic mechanisms across development and disease states, with particular emphasis on DNA methylation, chromatin dynamics, and epigenomic mapping of cell types. Member of the International Human Epigenome Consortium (IHEC) Coordinator of the German Epigenome Program Director of an in-house Sequencing Facility (HiSeq2500, Mi-Seq, Nextseq-500) Research focuses include: Epigenetic programming during cellular differentiation DNA methylation dynamics in disease contexts Stem cell epigenetics and reprogramming Evolution of epigenetic mechanisms Recent publications highlight interdisciplinary approaches combining next-generation sequencing , bioinformatic modeling , and clinical epigenetics , with particular attention to immune cell development , metabolic disease epigenetics , and computational epigenomics . The group maintains collaborations with the West German Sequencing Center and contributes to epigenetic data standardization efforts. Lab members include active researchers like Dr. Nina Gasparoni , Dr. Gilles Gasparoni , and M.Sc. Alea Leismann , alongside an extensive alumni network of former advisees who have advanced epigenetic research in various institutions.

Harriet Wikman-Kocherمشاهده پروفایل

استاد

• Cancer Biology
• Oncology
• Molecular Biology
• +۴ مورد دیگر

Prof. Dr. Harriet Wikman-Kocher is a Professor and Head of Research Group at the Institute of Tumor Biology, part of the Faculty of Medicine at the University of Hamburg. Her research focuses on liquid biopsy technologies, cancer metastasis, and molecular mechanisms in oncology, particularly in pancreatic, breast, lung, and brain cancers. She leads studies on circulating tumor cells (CTCs), cell-free DNA (ctDNA), and extracellular vesicles (EVs) to identify prognostic and diagnostic biomarkers. Her work integrates clinical and experimental approaches to advance understanding of tumor progression and therapeutic resistance. Expertise: Liquid biopsies, metastasis biology, CTCs/ctDNA analysis, cancer genomics, neuro-oncology. Key affiliations: University Medical Center Hamburg-Eppendorf (UKE), Center for Experimental Medicine. Her research emphasizes translational applications, such as improving early detection and monitoring of cancer through non-invasive methods. Collaborations include projects on immunotherapy biomarkers, brain metastasis mechanisms, and precision medicine strategies.

• Proteomics
• Metabolomics
• Plant-Microbe Interactions
• +۳ مورد دیگر

Prof. Dr. Karsten Niehaus serves as Head of the Proteome and Metabolome Research Group at the Center for Biotechnology (CeBiTec) and Faculty of Biology, University of Bielefeld. His research focuses on proteomics and metabolomics applications in plant-microbe interactions, bacterial stress responses, and disease model systems. His laboratory employs advanced mass spectrometry imaging and cell phenotyping technologies to investigate molecular responses in crops like sugar beet and grapevines under abiotic stress conditions, as well as in cancer models where differentiation therapy impacts tumor malignancy. The group also explores microbial biotechnology through Xanthomonas campestris studies on xanthan production and stress adaptation. Selected publications highlight innovations in 3D microfluidics for biomarker detection and bioinformatics platforms like MetHoS for metabolomics data analysis. His work appears in journals covering Frontiers in Plant Science , Scientific Reports , and Journal of Experimental Botany . Contact: kniehaus@cebitec.uni-bielefeld.de | Office: UHG W7-117

• Epigenetics
• Obesity
• Metabolic Diseases
• +۳ مورد دیگر

Maria Keller is Team Leader and Scientist at the Helmholtz-Institute for Metabolic, Obesity and Vascular Research (HI-MAG), Helmholtz Center Munich, hosted at the University of Leipzig since 2020. Previously, she served as Principal Investigator at the Integrated Research and Treatment Center-AdiposityDiseases (IFB) at the University of Leipzig (2018-2020) and completed postdoctoral training at Lund University Diabetes Centre and University of Leipzig Medical Center. Her academic foundation includes a Bachelor of Science in Ecotrophology from the University of Kiel and Master of Science in Nutritional Science from the University of Vienna, followed by a PhD from the University of Leipzig where she pioneered research on fat depot-specific DNA methylation patterns in obesity. Dr. Keller's research centers on epigenetic mechanisms in metabolic diseases, investigating how dietary polyphenols, bariatric surgery, and weight-loss interventions alter DNA methylation and gene expression in adipose tissue. Her work bridges molecular biology with clinical applications to identify biomarkers and therapeutic targets for obesity and type 2 diabetes. Analysis of her publications (2016-2024) reveals a cohesive trajectory from foundational epigenetic mechanisms to clinical translation, with increasing focus on dietary interventions like the green Mediterranean diet and weight-loss procedures. Her studies consistently leverage large-scale trials and advanced epigenomic techniques. She has received significant recognition including the 2024 Research Prize of the German Obesity Society, 2022 PreDoc-Mentor Award from Leipzig University, 2021 Research Award Lipidology, and 2016 DFG Postdoctoral Fellowship. Dr. Keller has supervised DNA methylation analyses for high-impact publications in Gut, Nature Communications, and Diabetes Care. Her mentorship excellence was acknowledged with the 2022 PreDoc-Mentor Award, and she secured competitive DFG funding for GeneXEnvironment interaction research. At HI-MAG, she leads a research team developing CRISPR-Cas9-based in vitro models to study gene-environment interactions, with recent work demonstrating that DNA methylation editing can reprogram adipogenesis and mirror metabolic remodeling after weight loss.

Dieter Saurمشاهده پروفایل

استاد

• Translational Cancer Research
• Genetic Alterations in Cancer
• Personalized Medicine
• +۳ مورد دیگر

Prof. Dieter Saur is a Professor of Translational Tumor Research at the Technical University of Munich (TUM) and Head of the Department at the German Cancer Research Center (DKFZ). His research focuses on developing personalized cancer therapies through mechanistic studies of tumor-relevant genetic alterations, with a particular emphasis on pancreatic and gastrointestinal cancers. Education: Studied medicine at Ludwig Maximilian University of Munich, earned a doctorate in neurogastroenterology, completed specialist training in gastroenterology and gastrointestinal oncology, and habilitation in internal medicine. He became a senior physician at University Hospital rechts der Isar before his current roles at TUM and DKFZ. Research Interests: Translational cancer research, genetic drivers of tumor progression, early detection methods, and targeted therapies for pancreatic and gastrointestinal cancers. He uses genetically engineered mouse models and organoid systems to study tumor heterogeneity and therapeutic resistance. Awards: Recipient of prestigious grants like the ERC Consolidator Grant (2015) and awards such as the Martin Wienbeck Award (2014) and Rising Star Award (2006). His work bridges basic science and clinical translation, emphasizing interdisciplinary approaches. Labs/Teams: Leads the Translational Tumor Research group at TUM and collaborates with the DKFZ to advance preclinical and clinical cancer research. Key projects include exploring KRAS signaling pathways, tumor microenvironment dynamics, and immune checkpoint therapies.